News
AbbVie has agreed to buy Capstan for up to $2.1bn, expanding its pipeline with an in vivo CAR-T therapy for autoimmune diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback